Protagonist Therapeutics Inc (PTGX)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | — | — | — |
| Debt-to-equity ratio | 0.00 | 0.00 | — | — | — |
| Financial leverage ratio | 1.10 | 1.06 | — | — | — |
Protagonist Therapeutics Inc shows strong solvency ratios based on the provided data. The Debt-to-assets ratio remained consistently at 0.00% from 2020 to 2024, indicating that the company has no debt in relation to its total assets during this period.
Similarly, both the Debt-to-capital and Debt-to-equity ratios were not available for 2020 and 2021 but stood at 0.00% for 2023 and 2024. This suggests that the company's debt in relation to its capital or equity is negligible, further underlining its strong financial position and low leverage.
The Financial leverage ratio, which reflects the company's level of financial risk, increased slightly from 1.06 in 2023 to 1.10 in 2024. While this indicates a marginal increase in leverage, the ratio is still relatively low, suggesting that Protagonist Therapeutics Inc relies more on equity financing rather than debt to support its operations.
Overall, based on these solvency ratios, Protagonist Therapeutics Inc appears to have a solid financial foundation with minimal debt obligations and a conservative approach to leverage, which can be positive indicators of financial stability and resilience.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | — | — | -38.99 | -50.72 | -107.78 |
Protagonist Therapeutics Inc's interest coverage has shown a declining trend over the years, indicating a deterioration in the company's ability to cover its interest expenses with operating income.
As of December 31, 2020, the interest coverage ratio was -107.78, highlighting that the company's operating income was insufficient to cover its interest expenses, raising concerns about its financial stability. This negative ratio suggests that the company may be at high risk of defaulting on its debt obligations.
Although there was an improvement in the interest coverage ratio by December 31, 2021, with a ratio of -50.72, the company still struggled to generate enough operating income to comfortably meet its interest payments.
By December 31, 2022, the interest coverage ratio further decreased to -38.99, indicating a persistent challenge for Protagonist Therapeutics Inc in managing its interest obligations.
The absence of data for December 31, 2023, and December 31, 2024, may suggest that the company's financial performance for those periods was not publicly disclosed or further analysis is required to assess the potential implications.
Overall, the consistently negative interest coverage ratios reflect a concerning financial situation for Protagonist Therapeutics Inc, highlighting the need for the company to address its operational efficiency and debt management to improve its financial health and sustainability.